Skip to main content

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Trial Status: Active

This is a global, Phase 1 / 2, multicenter, open-label study. The clinical study will include of Phase 1: Dose Escalation (non-randomized, dose finding study) and Phase 2: Dose Expansion (randomized efficacy exploration). For Phase 1, the purpose of this study is to assess the maximum tolerated dose (MTD), recommend phase 2 dose (RP2D), preliminary efficacy, and safety of selinexor in combination with SoC therapy for newly diagnosed glioblastoma multiforme (GBM) (nGBM) or recurrent GBM (rGBM). The study will independently evaluate 3 different combination regimens in 3 treatment arms in participants with nGBM O6-methylguanine-DNA-methyltransferase [MGMT] promotor unmethylated [uMGMT] disease in Arm A, MGMT methylated [mMGMT]) in Arm B, and participants with rGBM regardless of MGMT status in Arm C. The second phase of the study will compare selinexor+SoC treatments versus SoC treatment alone in the three treatment Arms.

Inclusion Criteria

  • Written informed consent in accordance with federal, local, and institutional Guidelines.
  • Age ≥18 years at the time of informed consent.
  • Pathologically confirmed glioblastoma (including all histological variants; documentation to be provided) that are newly diagnosed (for Arms A and B) or relapsed disease (for Arm C) after 1 line of systemic therapy (RT ± TMZ or RT ± TMZ in combination with other drug) that have not received the second line systemic treatment for relapsed disease (surgical resection of recurrent disease allowed). For Arms A and B, MGMT status should be available.
  • Prior therapy:
  • Arms A and B: participants who have not received radiation or any systemic therapy for brain tumor and must be eligible for definitive external beam radiotherapy and temozolomide
  • Arm C: participants must have received prior treatment with radiation therapy with or without temozolomide (and only 1 prior line of therapy) (RT ± TMZ in combination with other drug is allowed)
  • Measurable disease according to modified RANO guidelines is required only for Arm C; it is not required for Arms A or B.
  • Participants enrolling into Arm C must be on a stable or decreasing dose of corticosteroids (or none) for at least 5 days prior to the baseline magnetic resonance imaging (MRI).
  • Karnofsky Performance Score (KPS) ≥70 (for Arms A and B) and 60 (for Arm C).
  • Participants must have adequate organ function ≤2 weeks of study treatment as defined by the following laboratory criteria:
  • Hematological function ≤7 days prior to Cycle 1 Day 1: absolute neutrophil count (ANC) ≥1.5*10^9 per Liter (/L); platelet count ≥150*10^9/L; and hemoglobin (Hb) ≥10.0 gram per deciliter (g/dL). Transfusion is not allowed within 7 days prior to Cycle 1 Day 1
  • Hepatic function: bilirubin ≤2*the upper limit of normal (ULN), alanine transaminase (ALT) ≤2.5*ULN, aspartate transaminase (AST) ≤2.5*ULN; unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin must be <4*ULN
  • Renal function: calculated (Cockcroft-Gault) or measured creatinine clearance ≥30 milliliter per minute (mL/min)
  • Female participants of childbearing potential must have a negative serum pregnancy test at Screening and agree to use highly effective methods of contraception throughout the study and for 90 days following the last dose of study treatment.
  • Fertile male participants who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 4 months following the last dose of study treatment.
  • For Arms A and B: participants must have had surgery and/or biopsy not greater than [>] 8 weeks prior to initial screening.
  • Participants must consent to provide tumor tissue and blood samples to be used for future molecular testing for correlative studies.

Exclusion Criteria

  • Participants who are receiving any other investigational agents and /or have had prior therapy including: For Arms A and B only:
  • Participants who have previously received RT to the brain
  • Participants who received chemotherapy for the treatment of their glioma
  • Participants who are being treated with implanted Gliadel wafers For Arm C:
  • Less than (<) 6 weeks from nitrosourea (if ever received), <4 weeks from prior temozolomide or other chemotherapy, or <4 weeks or 5 half-lives (whichever is shorter) for investigational agents prior to start of study treatment
  • Prior treatment bevacizumab or other direct vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitors. For any questions of the definition of a direct VEGF/VEGFR inhibitor, consult the study Medical Monitor
  • Any AE which has not recovered to Grade less than or equal to (≤) 1, or returned to baseline, related to the previous GBM therapy, except alopecia, and some other grade 2 AEs that have been stabilized (upon Medical Monitor approval)
  • Participants who are being treated or plan to be treated during this study with tumor treating fields.
  • Major surgery <2 weeks prior to the start of study treatment.
  • History of allergic reactions attributed to compounds of similar chemical or biological composition to selinexor or other study treatment.
  • Participants must not have significantly diseased or obstructed gastrointestinal tract malabsorption, uncontrolled vomiting or diarrhea, or inability to swallow oral medication.
  • Participants with coagulation problems and medically significant bleeding in the month prior to start of treatment (peptic ulcers, epistaxis, spontaneous bleeding). Prior history of deep vein thrombosis or pulmonary embolism is not exclusionary.
  • Currently pregnant or breastfeeding.
  • For Arms A and B: participants with pre-existing known or suspected radiation sensitivity syndromes will be excluded due to potential confounding effect on outcome.
  • Any life-threatening illness, active medical condition, organ system dysfunction, or serious active psychiatric issue which, in the Investigator's opinion, could compromise the participant's safety or the participant's ability to remain compliant with study procedures.
  • Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable even if parenteral.
  • Participants with mutated isocitrate dehydrogenase (IDH) should be excluded for Phase 2.

California

San Francisco
University of California San Francisco
Status: ACTIVE
Contact: UCSF Clinical Trials
Phone: 877-827-3222

Illinois

Chicago
Northwestern University
Status: ACTIVE

Massachusetts

Boston
Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE
Massachusetts General Hospital Cancer Center
Status: ACTIVE

New Jersey

Hackensack
Hackensack University Medical Center
Status: ACTIVE

New York

New York
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: ACTIVE

Ohio

Cleveland
Case Comprehensive Cancer Center
Status: IN_REVIEW

Texas

Houston
M D Anderson Cancer Center
Status: ACTIVE

Utah

Salt Lake City
Huntsman Cancer Institute / University of Utah
Status: ACTIVE

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: ACTIVE

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Karyopharm Therapeutics Inc

  • Primary ID XPORT-GBM-029
  • Secondary IDs NCI-2020-04633, 2021-000080-67
  • Clinicaltrials.gov ID NCT04421378